drugset / Trial / NCT01894633

Study of Whole-brain Irradiation With Chloroquine for Brain Metastases

NCT01894633

Phase 2 Terminated 73 enrolled National Cancer Institute of Mexico
RandomizedParallel-groupDouble-blindTreatment

Summary

Background and purposes:Chloroquine (CLQ), an antimalarial drug, has a lysosomatrophic effect associate with increase the sensibility of Radiation through leakage of hidroliticenzimes, increase of apoptosis, autophagy mediated by lysosomalhidrolases and increase of oxidative stress "in vitro". In this phase II study we evaluated the efficacy and safety as radiosensitizing of the Chloroquine plus concomitant 30 Gray (Gy) of Whole-brain irradiation (WBI)in patients with brain metastases (BM) from solid tumors.

Timeline

Start
2011-05
Primary completion
2012-04
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloroquine Small molecule 150 mg Oral